BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M, Welsh D. The 1993 Walter Hubert Lecture: The role of the P53 tumor suppressor gene in the tumorigenesis. Br J Cancer. 1994;69:409-416. [PMID: 8123467 DOI: 10.1038/bjc.1994.76] [Cited by in Crossref: 270] [Cited by in F6Publishing: 285] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 De Jong KP, Stellema R, Karrenbeld A, Koudstaal J, Gouw AS, Sluiter WJ, Peeters PM, Slooff MJ, De Vries EG. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology. 1998;28:971-979. [PMID: 9755233 DOI: 10.1002/hep.510280411] [Cited by in Crossref: 78] [Cited by in F6Publishing: 78] [Article Influence: 3.4] [Reference Citation Analysis]
2 Mir R, Masroor M, Javid J, Ahamad I, Farooq S, Yadav P, Zuberi M, Lone M, Ray PC, Saxena A. Clinical implications of cytosine deletion of exon 5 of P53 gene in non small cell lung cancer patients. South Asian J Cancer 2016;5:33-6. [PMID: 27169122 DOI: 10.4103/2278-330X.179701] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
3 Russo A, Corsale S, Agnese V, Macaluso M, Cascio S, Bruno L, Surmacz E, Dardanoni G, Valerio MR, Vieni S, Restivo S, Fulfaro F, Tomasino RM, Gebbia N, Bazan V. TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma. J Cell Physiol 2006;206:181-8. [PMID: 15965904 DOI: 10.1002/jcp.20447] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
4 Seki A, Kodama J, Miyagi Y, Kamimura S, Yoshinouchi M, Kudo T. Amplification of themdm-2 gene andp53 abnormalities in uterine sarcomas. Int J Cancer 1997;73:33-7. [DOI: 10.1002/(sici)1097-0215(19970926)73:1<33::aid-ijc6>3.0.co;2-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
5 Gong S, Xu D, Zou F, Peng R. (−)-Curine induces cell cycle arrest and cell death in hepatocellular carcinoma cells in a p53-independent way. Biomedicine & Pharmacotherapy 2017;89:894-901. [DOI: 10.1016/j.biopha.2017.01.148] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
6 Shigemasa K, Hu C, West CM, Moon SH, Parham GP, Parmley TH, Korourian S, Baker VV, O'brien TJ. p21: a monitor of p53 dysfunction in ovarian neoplasia. Int J Gynecol Cancer 1997;7:296-303. [DOI: 10.1046/j.1525-1438.1997.00457.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
7 Danks RA, Chopra G, Gonzales MF, Orian JM, Kaye AH. Aberrant p53 Expression Does Not Correlate with the Prognosis in Anaplastic Astrocytoma. Neurosurgery 1995;37:246-54. [DOI: 10.1227/00006123-199508000-00009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
8 Williams JR, Russell J, Dicello JF, Mabry MH. The genotype of the human cancer cell: Implications for risk analysis. Mutation Research/Reviews in Genetic Toxicology 1996;365:17-42. [DOI: 10.1016/s0165-1110(96)90010-x] [Cited by in Crossref: 7] [Article Influence: 0.3] [Reference Citation Analysis]
9 Panizo C, Patiño A, Calasanz MJ, Rifón J, Sierrasesumaga L, Rocha E. Emergence of secondary acute leukemia in a patient treated for osteosarcoma: implications of germline TP53 mutations. Med Pediatr Oncol 1998;30:165-9. [PMID: 9434825 DOI: 10.1002/(sici)1096-911x(199803)30:3<165::aid-mpo7>3.0.co;2-f] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
10 Skomedal H, Kristensen GB, Abeler VM, Børresen-dale A, Tropé C, Holm R. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas. J Pathol 1997;181:158-65. [DOI: 10.1002/(sici)1096-9896(199702)181:2<158::aid-path742>3.0.co;2-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
11 Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O, Meyer F, Roessner A. Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia. 2004;6:529-535. [PMID: 15548361 DOI: 10.1593/neo.04178] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
12 Pauly M, Schmitz M, Kayser I, Türeci Ö, Lagoda P, Seitz G, Dicato M. Ki-ras oncogene and p53 tumour suppressor gene mutations in colorectal carcinomas from the European Saar-Luxembourg region are less frequent than predicted by the classic adenoma-carcinoma sequence model. European Journal of Cancer 1997;33:2265-72. [DOI: 10.1016/s0959-8049(97)00276-1] [Cited by in Crossref: 7] [Article Influence: 0.3] [Reference Citation Analysis]
13 Lujic N, Sopta J, Kovacevic R, Stevanovic V, Davidovic R. Recurrence of giant cell tumour of bone: role of p53, cyclin D1, β-catenin and Ki67. Int Orthop 2016;40:2393-9. [PMID: 27658412 DOI: 10.1007/s00264-016-3292-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
14 Schreiber S, Saeger W, Lüdecke DK. Proliferation markers in different types of clinically non-secreting pituitary adenomas. Pituitary 1999;1:213-20. [PMID: 11081200 DOI: 10.1023/a:1009933820856] [Cited by in Crossref: 42] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
15 Prendergast NJ, Atkins MR, Schatte EC, Paulson DF, Walther PJ. p53 Immunohistochemical and Genetic Alterations are Associated at High Incidence with Post-Irradiated Locally Persistent Prostate Carcinoma. Journal of Urology 1996;155:1685-92. [DOI: 10.1016/s0022-5347(01)66165-2] [Cited by in Crossref: 54] [Article Influence: 2.2] [Reference Citation Analysis]
16 Sladek TL. Established cell lines transformed by E2F-1 overexpression contain wild-type p53. Cell Prolif 1996;29:579-88. [DOI: 10.1111/j.1365-2184.1996.tb00973.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
17 Piffkó J, Bánkfalvi Á Á, Öfner D, Tötsch M, Berens A, Joos U, Böcker W, Schmid KW. Proliferative (MIB1, mdm2) Versus Anti-Proliferative (p53) Markers in Head and Neck Cancer. An Immunohistochemical Study. Pathol Oncol Res 1996;2:37-42. [PMID: 11173581 DOI: 10.1007/BF02893946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
18 Wang LS, Chow KC, Chi KH, Liu CC, Li WY, Chiu JH, Huang MH. Prognosis of esophageal squamous cell carcinoma: analysis of clinicopathological and biological factors. Am J Gastroenterol. 1999;94:1933-1940. [PMID: 10406262 DOI: 10.1111/j.1572-0241.1999.01233.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 3.2] [Reference Citation Analysis]
19 Kim H, You S, Farris J, Foster LK, Foster DN. Post-transcriptional inactivation of p53 in immortalized murine embryo fibroblast cells. Oncogene 2001;20:3306-10. [PMID: 11423980 DOI: 10.1038/sj.onc.1204423] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
20 Anderson D. Expression of ras (p21) protein in plasma from exposed workers and from patients with lung disease. Int J Hyg Environ Health 2001;204:55-60. [PMID: 11725347 DOI: 10.1078/1438-4639-00073] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
21 Rudolph P, Olsson H, Bonatz G, Ratjen V, Bolte H, Baldetorp B, Fern� M, Parwaresch R, Alm P. Correlation between p53, c-erbB-2, and topoisomerase II? expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol 1999;187:207-16. [DOI: 10.1002/(sici)1096-9896(199901)187:2<207::aid-path223>3.0.co;2-u] [Cited by in Crossref: 75] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
22 Spivack SD, Fasco MJ, Walker VE, Kaminsky LS. The Molecular Epidemiology of Lung Cancer. Critical Reviews in Toxicology 2008;27:319-65. [DOI: 10.3109/10408449709089898] [Cited by in Crossref: 64] [Cited by in F6Publishing: 50] [Article Influence: 4.9] [Reference Citation Analysis]
23 Schwab M. Oncogene amplification in solid tumors. Semin Cancer Biol. 1999;9:319-325. [PMID: 10448118 DOI: 10.1006/scbi.1999.0126] [Cited by in Crossref: 128] [Cited by in F6Publishing: 118] [Article Influence: 5.8] [Reference Citation Analysis]
24 O???connor MM, Mayberg MR. Effects of Radiation on Cerebral Vasculature: A Review: . Neurosurgery. [DOI: 10.1097/00006123-200001000-00026] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
25 Buttgereit P, Schakowski F, Märten A, Brand K, Renoth S, Ziske C, Schöttker B, Ebert O, Schroers R, Schmidt-wolf IG. Effects of adenoviral wild-type p53 gene transfer in p53 -mutated lymphoma cells. Cancer Gene Ther 2001;8:430-9. [DOI: 10.1038/sj.cgt.7700323] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
26 Pazzi KA, Kraegel SA, Griffey SM, Theon AP, Madewell BR. Analysis of the equine tumor suppressor gene p53 in the normal horse and in eight cutaneous squamous cell carcinomas. Cancer Lett 1996;107:125-30. [PMID: 8913276 DOI: 10.1016/0304-3835(96)04359-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
27 Birch J. Li-Fraumeni syndrome. European Journal of Cancer 1994;30:1935-41. [DOI: 10.1016/0959-8049(94)00383-g] [Cited by in Crossref: 39] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
28 Collins LL, Lin D, Mu X, Chang C. Feedback Regulation between Orphan Nuclear Receptor TR2 and Human Papilloma Virus Type 16. Journal of Biological Chemistry 2001;276:27316-21. [DOI: 10.1074/jbc.m104145200] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Sauer T, Beraki K, Furu I, Ormerod E, Jebsen PW, Naess O. Estimating loss of the wild-type p53 gene by in situ hybridization of fine-needle aspirates from breast carcinomas. Diagn Cytopathol 1999;20:266-70. [PMID: 10319226 DOI: 10.1002/(sici)1097-0339(199905)20:5<266::aid-dc4>3.0.co;2-6] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
30 Wiethege T, Voss B, Müller KM. P53 accumulation and proliferating-cell nuclear antigen expression in human lung cancer. J Cancer Res Clin Oncol 1995;121:371-7. [PMID: 7797603 DOI: 10.1007/BF01225691] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
31 Yanamoto S, Kawasaki G, Yoshitomi I, Mizuno A. Expression of p53R2, newly p53 target in oral normal epithelium, epithelial dysplasia and squamous cell carcinoma. Cancer Lett. 2003;190:233-243. [PMID: 12565178 DOI: 10.1016/s0304-3835(02)00588-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
32 Andreassen A, Kure EH, Nielsen PS, Autrup H, Haugen A. Comparative synchronous fluorescence spectrophotometry and 32P-postlabeling analysis of PAH-DNA adducts in human lung and the relationship to TP53 mutations. Mutat Res 1996;368:275-82. [PMID: 8692233 DOI: 10.1016/s0165-1218(96)90069-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
33 Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008;7:1001-12. [DOI: 10.1038/nrd2637] [Cited by in Crossref: 299] [Cited by in F6Publishing: 274] [Article Influence: 23.0] [Reference Citation Analysis]
34 Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma: p53 Alterations and Ovarian Carcinoma Prognosis. Cancer 2000;89:2006-17. [DOI: 10.1002/1097-0142(20001101)89:9<2006::aid-cncr18>3.0.co;2-7] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
35 Van PL, Yim KW, Jin DY, Dapolito G, Kurimasa A, Jeang KT. Genetic evidence of a role for ATM in functional interaction between human T-cell leukemia virus type 1 Tax and p53. J Virol 2001;75:396-407. [PMID: 11119608 DOI: 10.1128/JVI.75.1.396-407.2001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
36 Farrell WE, Clayton RN. Molecular biology of human pituitary adenomas. Annals of Medicine 2009;30:192-8. [DOI: 10.3109/07853899808999403] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
37 Polge A, Bourgaux JF, Bancel E, Pignodel C, Boyer JC, Poirey S, de Bornier BM, Balmes JL, Bali JP. p53 and follow-up of colorectal adenocarcinomas. Dig Dis Sci 1998;43:1434-42. [PMID: 9690377 DOI: 10.1023/a:1018890126260] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
38 Vautier G, Bomford AB, Portmann BC, Metivier E, Williams R, Ryder SD. p53 mutations in British patients with hepatocellular carcinoma: Clustering in genetic hemochromatosis. Gastroenterology 1999;117:154-60. [DOI: 10.1016/s0016-5085(99)70562-7] [Cited by in Crossref: 62] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
39 Mangini J, Li N, Bhawan J. Immunohistochemical Markers of Melanocytic Lesions: A Review of Their Diagnostic Usefulness. The American Journal of Dermatopathology 2002;24:270-81. [DOI: 10.1097/00000372-200206000-00016] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
40 Kim S, Kim J, Kim Y, Kim J, Yoon B, Ryu H. Prognostic factors and expression of p53 and mdm-2 in uterine sarcomas. International Journal of Gynecology & Obstetrics 2006;95:272-7. [DOI: 10.1016/j.ijgo.2006.03.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
41 Jeffers MD, Farquharson MA, Richmond JA, Mcnicol AM. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus. J Pathol 1995;177:65-70. [DOI: 10.1002/path.1711770111] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 1.9] [Reference Citation Analysis]
42 Lemasson I, Nyborg JK. Human T-cell leukemia virus type I tax repression of p73beta is mediated through competition for the C/H1 domain of CBP. J Biol Chem 2001;276:15720-7. [PMID: 11279015 DOI: 10.1074/jbc.M100131200] [Cited by in Crossref: 38] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
43 Blom, Malmstrom, Guerrieri. Endometrial stromal sarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 17 cases. Int J Gynecol Cancer 1999;9:98-104. [DOI: 10.1046/j.1525-1438.1999.09870.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
44 Chapman RS, Gregory CD, Dive C. Apoptosis in Hematopoiesis and Leukemogenesis. In: Whetton AD, Gordon J, editors. Blood Cell Biochemistry. Boston: Springer US; 1996. pp. 151-201. [DOI: 10.1007/978-0-585-31728-1_7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
45 Harris CC. The 1995 Walter Hubert Lecture--molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. Br J Cancer 1996;73:261-9. [PMID: 8562328 DOI: 10.1038/bjc.1996.47] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 3.0] [Reference Citation Analysis]
46 Suresh TN, Hemalatha A, Harendra Kumar ML, Azeem Mohiyuddin SM. Evaluation of histomorphological and immunohistochemical parameters as biomarkers of cervical lymph node metastasis in squamous cell carcinoma of oral cavity: A retrospective study. J Oral Maxillofac Pathol 2015;19:18-24. [PMID: 26097301 DOI: 10.4103/0973-029X.157195] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
47 Hainaut P, Butcher S, Milner J. Temperature sensitivity for conformation is an intrinsic property of wild-type p53. Br J Cancer 1995;71:227-31. [PMID: 7841034 DOI: 10.1038/bjc.1995.48] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 1.5] [Reference Citation Analysis]
48 Whiteman DC, Parsons PG, Green AC. p53 expression and risk factors for cutaneous melanoma: A case-control study. Int J Cancer 1998;77:843-8. [DOI: 10.1002/(sici)1097-0215(19980911)77:6<843::aid-ijc8>3.0.co;2-u] [Cited by in Crossref: 102] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
49 Alrawi SJ, Deeb G, Cheney R, Wallace P, Loree T, Rigual N, Hicks W, Tan D. Lipomatous hemangiopericytoma of the head and neck: immunohistochemical and DNA ploidy analyses. Head Neck. 2004;26:544-549. [PMID: 15162357 DOI: 10.1002/hed.20054] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
50 Maehara Y, Emi Y, Tomisaki S, Oshiro T, Kakeji Y, Ichiyoshi Y, Sugimachi K. Age-related characteristics of gastric carcinoma in young and elderly patients. Cancer 1996;77:1774-80. [PMID: 8646673 DOI: 10.1002/(SICI)1097-0142(19960501)77:9<1774::AID-CNCR3>3.0.CO;2-C] [Cited by in Crossref: 45] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
51 Nagata Y, Anan T, Yoshida T, Mizukami T, Taya Y, Fujiwara T, Kato H, Saya H, Nakao M. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association. Oncogene. 1999;18:6037-6049. [PMID: 10557093 DOI: 10.1038/sj.onc.1202978] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 3.4] [Reference Citation Analysis]
52 孟华, 刘丽娜, 孟晓光. 胃癌及癌前病变中PCNA、p53表达及其与H. pylori感染的关系. 世界华人消化杂志 2005; 13(10): 1253-1255 [DOI: 10.11569/wcjd.v13.i10.1253] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
53 Nagashima M, Shiseki M, Miura K, Hagiwara K, Linke SP, Pedeux R, Wang XW, Yokota J, Riabowol K, Harris CC. DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc Natl Acad Sci USA. 2001;98:9671-9676. [PMID: 11481424 DOI: 10.1073/pnas.161151798] [Cited by in Crossref: 132] [Cited by in F6Publishing: 133] [Article Influence: 6.6] [Reference Citation Analysis]
54 Ilmonen S, Vaheri A, Asko-Seljavaara S, Carpen O. Ezrin in primary cutaneous melanoma. Mod Pathol 2005;18:503-10. [PMID: 15475929 DOI: 10.1038/modpathol.3800300] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 4.4] [Reference Citation Analysis]
55 Ljungman M. Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. Neoplasia 2000;2:208-25. [PMID: 10935507 DOI: 10.1038/sj.neo.7900073] [Cited by in Crossref: 135] [Cited by in F6Publishing: 135] [Article Influence: 6.4] [Reference Citation Analysis]
56 Manning FC, Patierno SR. Apoptosis: inhibitor or instigator of carcinogenesis. Cancer Invest. 1996;14:455-465. [PMID: 8816861 DOI: 10.3109/07357909609018903] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 1.9] [Reference Citation Analysis]
57 Gissi DB, Gabusi A, Servidio D, Cervellati F, Montebugnoli L. Predictive Role of p53 Protein as a Single Marker or Associated with ki67 Antigen in Oral Leukoplakia: A Retrospective Longitudinal Study. Open Dent J 2015;9:41-5. [PMID: 25674170 DOI: 10.2174/1874210601509010041] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
58 Loging WT, Reisman D. Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53. Oncogene 1999;18:7608-15. [PMID: 10602522 DOI: 10.1038/sj.onc.1203135] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.3] [Reference Citation Analysis]
59 Ikuta A, Saito J, Mizokami T, Nakamoto T, Yasuhara M, Nagata F, Nakajima M, Matsuo I, Yasuda K, Kanzaki H. Correlation p53 expression and human papilloma virus deoxyribonucleic acid with clinical outcome in early uterine cervical carcinoma. Cancer Detection and Prevention 2005;29:528-36. [DOI: 10.1016/j.cdp.2005.09.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
60 Lopes MA, Nikitakis NG, Reynolds MA, Ord RA, Sauk J. Biomarkers predictive of lymph node metastases in oral squamous cell carcinoma. Journal of Oral and Maxillofacial Surgery 2002;60:142-7. [DOI: 10.1053/joms.2002.29804] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
61 Dornelas MT, Rodrigues MF, Machado DC, Gollner AM, Ferreira AP. [Expression of cell proliferation and apoptosis biomarkers in skin spinocellular carcinoma and actinic keratosis]. An Bras Dermatol 2009;84:469-75. [PMID: 20098848 DOI: 10.1590/s0365-05962009000500004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
62 Chava S, Mohan V, Shetty PJ, Manolla ML, Vaidya S, Khan IA, Waseem GL, Boddala P, Ahuja YR, Hasan Q. Immunohistochemical evaluation of p53, FHIT, and IGF2 gene expression in esophageal cancer. Dis Esophagus 2012;25:81-7. [PMID: 21668571 DOI: 10.1111/j.1442-2050.2011.01213.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
63 Riethdorf S, Friedrich RE, Ostwald C, Batten M, Gogacz P, Gundlach KKH, Schlechte H, Becker J, Bregenzer T, Riethdorf L, Loning T. p53 gene mutations and HPV infection in primary head and neck squamous cell carcinomas do not correlate with overall survival: a long term follow-up study. J Oral Pathol Med 1997;26:315-21. [DOI: 10.1111/j.1600-0714.1997.tb00222.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 1.8] [Reference Citation Analysis]
64 Anderson D, Hughes J, Cebulska-wasilewska A, Nizankowska E, Graca B. ras oncoproteins in human plasma from lung cancer patients and healthy controls. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1996;349:121-6. [DOI: 10.1016/0027-5107(95)00168-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
65 Sawasaki T, Shigemasa K, Shiroyama Y, Kusuda T, Fujii T, Parmley TH, O'brien TJ, Ohama K. Cyclin E mRNA Overexpression in Epithelial Ovarian Cancers: Inverse Correlation with p53 Protein Accumulation. Journal of the Society for Gynecologic Investigation 2016;8:179-85. [DOI: 10.1177/107155760100800310] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
66 de Freitas Mda C, Ramalho LM, Xavier FC, Moreira AL, Reis SR. p53 and MDM2 protein expression in actinic cheilitis. J Appl Oral Sci 2008;16:414-9. [PMID: 19082401 DOI: 10.1590/s1678-77572008000600011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
67 Giebler HA, Lemasson I, Nyborg JK. p53 recruitment of CREB binding protein mediated through phosphorylated CREB: a novel pathway of tumor suppressor regulation. Mol Cell Biol 2000;20:4849-58. [PMID: 10848610 DOI: 10.1128/MCB.20.13.4849-4858.2000] [Cited by in Crossref: 59] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
68 Schmider A, Gee C, Friedmann W, Lukas JJ, Press MF, Lichtenegger W, Reles A. p21 (WAF1/CIP1) Protein Expression Is Associated with Prolonged Survival but Not with p53 Expression in Epithelial Ovarian Carcinoma. Gynecologic Oncology 2000;77:237-42. [DOI: 10.1006/gyno.2000.5748] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 1.8] [Reference Citation Analysis]
69 Schweizer P. Linear Dose-response Relationship and No Inverse Dose-rate Effect Observed for Low X-ray Dose-induced Mitotic Recombination in Drosophila Melanogaster. International Journal of Radiation Biology 2009;67:303-13. [DOI: 10.1080/09553009514550361] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
70 Siemion IZ, Strug I, Wieczorek Z. Length of the peptide chain influences the immunomodulatory activity of peptides related to p53 protein. Peptides 1999;20:995-8. [DOI: 10.1016/s0196-9781(99)00087-x] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
71 Siles E, Villalobos M, Valenzuela MT, Núñez MI, Gordon A, McMillan TJ, Pedraza V, Ruiz de Almodóvar JM. Relationship between p53 status and radiosensitivity in human tumour cell lines. Br J Cancer 1996;73:581-8. [PMID: 8605090 DOI: 10.1038/bjc.1996.101] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 1.8] [Reference Citation Analysis]
72 Shi YF, Xie X, Zhao CL, Ye DF, Lu SM, Hor JJ, Pao CC. Lack of mutation in tumour-suppressor gene p53 in gestational trophoblastic tumours. Br J Cancer 1996;73:1216-9. [PMID: 8630281 DOI: 10.1038/bjc.1996.233] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.2] [Reference Citation Analysis]
73 Barbatis C, Loukas L, Grigoriou M, Nikolaou I, Tsikou-Papafragou A, Marsan N, Gatter KC, Kaklamanis L. p53 Overexpression in laryngeal squamous cell carcinoma and dysplasia. Clin Mol Pathol 1995;48:M194-7. [PMID: 16696005 DOI: 10.1136/mp.48.4.m194] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
74 Poon GM, Brokx RD, Sung M, Gariépy J. Tandem Dimerization of the Human p53 Tetramerization Domain Stabilizes a Primary Dimer Intermediate and Dramatically Enhances its Oligomeric Stability. Journal of Molecular Biology 2007;365:1217-31. [DOI: 10.1016/j.jmb.2006.10.051] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
75 Lingen MW, Chang KW, McMurray SJ, Solt DB, Kies MS, Mittal BB, Haines GK, Pelzer HJ. Overexpression of p53 in squamous cell carcinoma of the tongue in young patients with no known risk factors is not associated with mutations in exons 5-9. Head Neck 2000;22:328-35. [PMID: 10862014 DOI: 10.1002/1097-0347(200007)22:4<328::aid-hed3>3.0.co;2-r] [Cited by in Crossref: 61] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
76 Lee H, Larner JM, Hamlin JL. Cloning and characterization of Chinese hamster p53 cDNA. Gene 1997;184:177-83. [DOI: 10.1016/s0378-1119(96)00592-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
77 Hafez NH, Tahoun NS. Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions. Journal of the Egyptian National Cancer Institute 2011;23:155-62. [DOI: 10.1016/j.jnci.2011.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
78 Jin S, Martinek S, Joo WS, Wortman JR, Mirkovic N, Sali A, Yandell MD, Pavletich NP, Young MW, Levine AJ. Identification and characterization of a p53 homologue in Drosophila melanogaster. Proc Natl Acad Sci U S A 2000;97:7301-6. [PMID: 10860994 DOI: 10.1073/pnas.97.13.7301] [Cited by in Crossref: 142] [Cited by in F6Publishing: 148] [Article Influence: 6.8] [Reference Citation Analysis]
79 Hartmann A, Blaszyk H, Kovach JS, Sommer SS. The molecular epidemiology of P53 gene mutations in human breast cancer. Trends in Genetics 1997;13:27-33. [DOI: 10.1016/s0168-9525(96)10043-3] [Cited by in Crossref: 88] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
80 Macera M, Godec C, Sharma N, Verma R. Loss of Heterozygosity of the TP53 Tumor Suppressor Gene and Detection of Point Mutations by the Non-Isotopic RNAse Cleavage Assay in Prostate Cancer. Cancer Genetics and Cytogenetics 1999;108:42-7. [DOI: 10.1016/s0165-4608(98)00109-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
81 Nylander K, Nilsson P, Mehle C, Roos G. p53 mutations, protein expression and cell proliferation in squamous cell carcinomas of the head and neck. Br J Cancer 1995;71:826-30. [PMID: 7710950 DOI: 10.1038/bjc.1995.159] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 2.1] [Reference Citation Analysis]
82 Livengood JA, Scoggin KE, Van Orden K, McBryant SJ, Edayathumangalam RS, Laybourn PJ, Nyborg JK. p53 Transcriptional activity is mediated through the SRC1-interacting domain of CBP/p300. J Biol Chem 2002;277:9054-61. [PMID: 11782467 DOI: 10.1074/jbc.M108870200] [Cited by in Crossref: 47] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
83 Shi ZG, Li SQ, Li ZJ, Zhu XJ, Xu P, Liu G. Expression of vimentin and survivin in clear cell renal cell carcinoma and correlation with p53. Clin Transl Oncol 2015;17:65-73. [PMID: 25028191 DOI: 10.1007/s12094-014-1199-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
84 Kuo T, Hu S, Lo S, Chan H. p53 expression and proliferative activity in Bowen's disease with or without chronic arsenic exposure. Human Pathology 1997;28:786-90. [DOI: 10.1016/s0046-8177(97)90150-7] [Cited by in Crossref: 12] [Article Influence: 0.5] [Reference Citation Analysis]
85 Sankalecha TH, Gupta SJ, Gaikwad NR, Shirole NU, Kothari HG. Yield of p53 expression in esophageal squamous cell cancer and its relationship with survival. Saudi J Gastroenterol 2017;23:281-6. [PMID: 28937022 DOI: 10.4103/sjg.SJG_56_17] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
86 Oh JH, Kim H, Kim H, Kim WH, Lee SH. Aberrant Methylation of p14ARF Gene Correlates with Poor Survival in Osteosarcoma. Clinical Orthopaedics & Related Research 2006;442:216-22. [DOI: 10.1097/01.blo.0000188063.56091.69] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
87 Onur C, Orhan D, Orhan M, Sak SD, Tulunay Ö, İrkeç M. Expression of p53 Protein in Pterygium. European Journal of Ophthalmology 1998;8:157-61. [DOI: 10.1177/112067219800800307] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
88 Meng L, Lin L, Zhang H, Nassiri M, Morales AR, Nadji M. Multiple mutations of the p53 gene in human mammary carcinoma. Mutat Res 1999;435:263-9. [PMID: 10606817 DOI: 10.1016/s0921-8777(99)00053-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
89 Blaylock RL. Neurodegeneration and Aging of the Central Nervous System. Integrative Medicine 1998;1:117-33. [DOI: 10.1016/s1096-2190(98)00032-8] [Cited by in Crossref: 7] [Article Influence: 0.3] [Reference Citation Analysis]
90 Bolewska-pedyczak E, Siemion IZ, Wieczorek Z. The Immunomodulatory Activity of Peptides Related to the DNA Contacting Loop of p53 Protein. J Peptide Sci 1996;2:318-24. [DOI: 10.1002/psc.68] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
91 Daidone MG, Benini E, Rao S, Pilotti S, Silvestrini R. Fixation Time and Microwave Oven Irradiation Affect Immunocytochemical p53 Detection in Formalin-Fixed Paraffin Sections: . Applied Immunohistochemistry 1998;6:140-4. [DOI: 10.1097/00022744-199809000-00006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
92 Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013;19:5777-5787. [PMID: 23983256 DOI: 10.1158/1078-0432.ccr-13-0351] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
93 Robbins P. p53 and Breast Cancer. Int J Surg Pathol 1996;4:93-110. [DOI: 10.1177/106689699600400206] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
94 Richardson A. Is breast cancer caused by late exposure to a common virus? Med Hypotheses 1997;48:491-7. [PMID: 9247892 DOI: 10.1016/s0306-9877(97)90118-3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
95 Biroccio A, Benassi B, D'Agnano I, D'Angelo C, Buglioni S, Mottolese M, Ricciotti A, Citro G, Cosimelli M, Ramsay RG, Calabretta B, Zupi G. c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am J Pathol 2001;158:1289-99. [PMID: 11290547 DOI: 10.1016/S0002-9440(10)64080-1] [Cited by in Crossref: 86] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
96 Smith DR, Ji CY, Goh HS. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer 1996;74:216-23. [PMID: 8688324 DOI: 10.1038/bjc.1996.340] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 2.3] [Reference Citation Analysis]
97 Giordano G, Azzoni C, D'Adda T, Rocco A, Gnetti L, Froio E, Merisio C, Melpignano M. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms. Pathol Res Pract 2008;204:163-74. [PMID: 18180113 DOI: 10.1016/j.prp.2007.11.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
98 Kmet LM, Cook LS, Magliocco AM. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer 2003;97:389-404. [PMID: 12518363 DOI: 10.1002/cncr.11064] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 3.8] [Reference Citation Analysis]
99 Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER. p53 Expression in Pituitary Adenomas and Carcinomas: Correlation with Invasiveness and Tumor Growth Fractions. Neurosurgery 1996;38:765-71. [DOI: 10.1227/00006123-199604000-00027] [Cited by in Crossref: 172] [Cited by in F6Publishing: 95] [Article Influence: 6.9] [Reference Citation Analysis]
100 Pietersen AM, van der Eb MM, Rademaker HJ, van den Wollenberg DJM, Rabelink MJWE, Kuppen PJK, van Dierendonck JH, van Ormondt H, Masman D, van de Velde CJH, van der Eb AJ, Hoeben RC, Noteborn MHM. Specific tumor-cell killing with adenovirus vectors containing the apoptin gene. Gene Ther 1999;6:882-92. [DOI: 10.1038/sj.gt.3300876] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 3.3] [Reference Citation Analysis]
101 Nagai MA, Miracca EC, Yamamoto L, Kowalski LP, Brentani RR. TP53 mutations in upper aerodigestive squamous cell carcinomas from a group of brazilian patients. The American Journal of Surgery 1995;170:492-4. [DOI: 10.1016/s0002-9610(99)80337-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
102 Ioffe OB, Papadimitriou JC, Drachenberg CB. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbb-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Human Pathology 1998;29:1150-9. [DOI: 10.1016/s0046-8177(98)90429-4] [Cited by in Crossref: 67] [Cited by in F6Publishing: 9] [Article Influence: 2.9] [Reference Citation Analysis]
103 Lai H, Lai S, Ma F, Meng L, Trapido E. Prevalence and Spectrum of p53 Mutations in White Hispanic and Non-Hispanic Women with Breast Cancer. Breast Cancer Res Treat 2003;81:53-60. [DOI: 10.1023/a:1025422905655] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
104 Goldsmith ME, Gudas JM, Schneider E, Cowan KH. Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J Biol Chem. 1995;270:1894-1898. [PMID: 7829527 DOI: 10.1074/jbc.270.4.1894] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
105 Zölzer F, Streffer C. Increased radiosensitivity with chronic hypoxia in four human tumor cell lines. International Journal of Radiation Oncology*Biology*Physics 2002;54:910-20. [DOI: 10.1016/s0360-3016(02)02963-2] [Cited by in Crossref: 62] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
106 Dang M, Lysack JT, Wu T, Matthews TW, Chandarana SP, Brockton NT, Bose P, Bansal G, Cheng H, Mitchell JR, Dort JC. MRI texture analysis predicts p53 status in head and neck squamous cell carcinoma. AJNR Am J Neuroradiol 2015;36:166-70. [PMID: 25258367 DOI: 10.3174/ajnr.A4110] [Cited by in Crossref: 49] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
107 Brock CS, Bower M. Current perspectives in gliomas. Med Oncol 1997;14:103-20. [PMID: 9330270 DOI: 10.1007/BF02990955] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
108 Fukami T, Nakasu S, Baba K, Nakajima M, Matsuda M. Hyperthermia induces translocation of apoptosis-inducing factor (AIF) and apoptosis in human glioma cell lines. J Neurooncol. 2004;70:319-331. [PMID: 15662973 DOI: 10.1007/s11060-004-9168-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
109 Ham S, van der Graaf W, Pras E, Molenaar W, van den Berg E, Hoekstra H. Soft tissue sarcoma of the extremities. A multimodality diagnostic and therapeutic approach. Cancer Treatment Reviews 1998;24:373-91. [DOI: 10.1016/s0305-7372(98)90001-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
110 Kim H, You S, Foster LK, Farris J, Foster DN. The rapid destabilization of p53 mRNA in immortal chicken embryo fibroblast cells. Oncogene 2001;20:5118-23. [PMID: 11526500 DOI: 10.1038/sj.onc.1204664] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
111 Regezi JA, Zarbo RJ, Regev E, Pisanty S, Silverman S, Gazit D. p53 protein expression in sequential biopsies of oral dysplasias and in situ carcinomas. J Oral Pathol Med 1995;24:18-22. [DOI: 10.1111/j.1600-0714.1995.tb01124.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 2.1] [Reference Citation Analysis]
112 Slootweg PJ. Suppressor Protein p53 and Its Occurrence in Oral Tumours. In: Seifert G, editor. Oral Pathology. Berlin: Springer Berlin Heidelberg; 1996. pp. 179-200. [DOI: 10.1007/978-3-642-80169-3_6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
113 Niklinska W, Burzykowski T, Chyczewski L, Rusin MR, Furman M, Laudanski J, Chyczewska E, Sulik M, Niklinski J. p53 gene mutation and protein expression in operable non-small cell lung cancer in Poland: . European Journal of Cancer Prevention 2000;9:81-8. [DOI: 10.1097/00008469-200004000-00003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
114 Saini KS, Walker NI. Biochemical and molecular mechanisms regulating apoptosis. Mol Cell Biochem. 1998;178:9-25. [PMID: 9546577 DOI: 10.1023/a:1006891430596] [Cited by in Crossref: 38] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
115 Niskanen E, Blomqvist C, Franssila K, Hietanen P, Wasenius VM. Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br J Cancer 1997;76:917-22. [PMID: 9328152 DOI: 10.1038/bjc.1997.484] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 2.2] [Reference Citation Analysis]
116 Kawashima K, Mihara K, Usuki H, Shimizu N, Namba M. Transfected mutantp53 gene increases X-ray-induced cell killing and mutation in human fibroblasts immortalized with 4-nitroquinoline 1-oxide but does not induce neoplastic transformation of the cells. Int J Cancer 1995;61:76-9. [DOI: 10.1002/ijc.2910610113] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.6] [Reference Citation Analysis]
117 Mao Y, Mehl IR, Muller MT. Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status. Proc Natl Acad Sci U S A 2002;99:1235-40. [PMID: 11805286 DOI: 10.1073/pnas.022631899] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 1.8] [Reference Citation Analysis]
118 Cummings MC. Increased p53 mRNA expression in liver and kidney apoptosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1996;1315:100-4. [DOI: 10.1016/0925-4439(95)00104-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
119 Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER. p53 Expression in Pituitary Adenomas and Carcinomas: Correlation with Invasiveness and Tumor Growth Fractions: . Neurosurgery. [DOI: 10.1097/00006123-199604000-00027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
120 Kleihues P, Aguzzi A, Ohgaki H. Genetic and environmental factors in the etiology of human brain tumors. Toxicology Letters 1995;82-83:601-5. [DOI: 10.1016/0378-4274(95)03503-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
121 Mayr B, Resch S, Hepperle S, Brem G, Reifinger M, Schaffner G. Comparative Studies in the Promoter and Exon 1 Regions of Tumour Suppressor p53 in Several Mammalian Species: Absence of Mutations in a Panel of Spontaneous Domestic Animal Tumours. J Vet Med Series A 2000;47:593-7. [DOI: 10.1046/j.1439-0442.2000.00322.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
122 Jennings MT, Pietenpol JA. The role of transforming growth factor beta in glioma progression. J Neurooncol 1998;36:123-40. [PMID: 9525812 DOI: 10.1023/a:1005863419880] [Cited by in Crossref: 64] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
123 Poon G. Enhancement of oligomeric stability by covalent linkage and its application to the human p53tet domain: thermodynamics and biological implications. Biochemical Society Transactions 2007;35:1574-8. [DOI: 10.1042/bst0351574] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
124 Ozaki T, Watanabe K, Nakagawa T, Miyazaki K, Takahashi M, Nakagawara A. Function of p73, not of p53, is inhibited by the physical interaction with RACK1 and its inhibitory effect is counteracted by pRB. Oncogene 2003;22:3231-42. [DOI: 10.1038/sj.onc.1206382] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 1.9] [Reference Citation Analysis]
125 Cornelis RS, van Vliet M, van de Vijver MJ, Vasen HF, Voute PA, Top B, Khan PM, Devilee P, Cornelisse CJ. Three germline mutations in the TP53 gene. Hum Mutat 1997;9:157-63. [PMID: 9067756 DOI: 10.1002/(SICI)1098-1004(1997)9:2<157::AID-HUMU8>3.0.CO;2-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
126 Lee J, Beliakoff J, Sun Z. The novel PIAS-like protein hZimp10 is a transcriptional co-activator of the p53 tumor suppressor. Nucleic Acids Res 2007;35:4523-34. [PMID: 17584785 DOI: 10.1093/nar/gkm476] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
127 Ferrándiz C, Fuente MJ, Fernández-figueras MT, Bielsa I, Just M. P53 Immunohistochemical Expression in Early Posttransplant-Associated Malignant and Premalignant Cutaneous Lesions: . Dermatologic Surgery 1999;25:97-101. [DOI: 10.1046/j.1524-4725.1999.08091.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
128 Levine AJ, Wu MC, Chang A, Silver A, Attiyeh EF, Lin J, Epstein CB. The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype. Ann N Y Acad Sci 1995;768:111-28. [PMID: 8526340 DOI: 10.1111/j.1749-6632.1995.tb12115.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 2.9] [Reference Citation Analysis]
129 Carson D, Lois A. Cancer progression and p53. The Lancet 1995;346:1009-11. [DOI: 10.1016/s0140-6736(95)91693-8] [Cited by in Crossref: 108] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
130 Abdel-Fattah R, Challen C, Griffiths TR, Robinson MC, Neal DE, Lunec J. Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer 1998;77:2230-8. [PMID: 9649138 DOI: 10.1038/bjc.1998.371] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 1.9] [Reference Citation Analysis]
131 Danks RA, Chopra G, Gonzales MF, Orian JM, Kaye AH. Aberrant p53 Expression Does Not Correlate with the Prognosis in Anaplastic Astrocytoma: . Neurosurgery 1995;37:246???254. [DOI: 10.1097/00006123-199508000-00009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
132 Piffko J, Bankfalvi A, Ofner D, Berens A, Tkotz T, Joos U, Bocker W, Schmid KW. Expression of p53 protein in oral squamous cell carcinomas and adjacent non-tumorous mucosa of the floor of the mouth: an archival immunohistochemical study using wet autoclave pretreatment for antigen retrieval. J Oral Pathol Med 1995;24:337-42. [DOI: 10.1111/j.1600-0714.1995.tb01196.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
133 Yu H, Levesque MA, Clark GM, Diamandis EP. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. Br J Cancer 1999;81:490-5. [PMID: 10507775 DOI: 10.1038/sj.bjc.6690720] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
134 Mankin HJ, Mankin KP, Harmon DC. Liposarcoma: a soft tissue tumor with many presentations. Musculoskelet Surg. 2014;98:171-177. [PMID: 25047632 DOI: 10.1007/s12306-014-0332-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
135 Stierum R, Conesa A, Heijne W, Ommen Bv, Junker K, Scott MP, Price RJ, Meredith C, Lake BG, Groten J. Transcriptome analysis provides new insights into liver changes induced in the rat upon dietary administration of the food additives butylated hydroxytoluene, curcumin, propyl gallate and thiabendazole. Food Chem Toxicol 2008;46:2616-28. [PMID: 18539377 DOI: 10.1016/j.fct.2008.04.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
136 Trulson JA, Millhauser GL. The effect of mutations on peptide models of the DNA binding helix of p53: Evidence for a correlation between structure and tumorigenesis. Biopolymers 1999;49:215-24. [DOI: 10.1002/(sici)1097-0282(199903)49:3<215::aid-bip3>3.0.co;2-f] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
137 Hao XP, Frayling IM, Sgouros JG, Du MQ, Willcocks TC, Talbot IC, Tomlinson IP. The spectrum of p53 mutations in colorectal adenomas differs from that in colorectal carcinomas. Gut 2002;50:834-9. [PMID: 12010886 DOI: 10.1136/gut.50.6.834] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
138 Li H, Tsao S, Cheung A. Current Understandings of the Molecular Genetics of Gestational Trophoblastic Diseases. Placenta 2002;23:20-31. [DOI: 10.1053/plac.2001.0744] [Cited by in Crossref: 71] [Cited by in F6Publishing: 59] [Article Influence: 3.7] [Reference Citation Analysis]
139 Sironi G, Riccaboni P. A case of equine cholangiocarcinoma displaying aberrant expression of p53 protein. Veterinary Record 1997;141:77-8. [DOI: 10.1136/vr.141.3.77] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
140 Villadsen R, Nielsen KV, Bolund L, Briand P. Complete Loss of Wild-Type TP53 in a Nontransformed Human Epithelial Cell Line Is Preceded by a Phase During Which a Heterozygous TP53 Mutant Effectively Outgrows the Homozygous Wild-Type Cells. Cancer Genetics and Cytogenetics 2000;116:28-34. [DOI: 10.1016/s0165-4608(99)00112-0] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
141 Daidone MG, Benini E, Valentinis B, Tomasic G, Bolis G, Villa A, Silvestrini R. p53 expression, DNA content and cell proliferation in primary and synchronous metastatic lesions from ovarian surface epithelial-stromal tumours. Eur J Cancer 1996;32A:1388-93. [PMID: 8869104 DOI: 10.1016/0959-8049(96)00101-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
142 Diaz-cascajo C, Bastida-inarrea J, Borrego L, Carretero-hernandez G. Comparison of p53 expression in dermatofibrosarcoma protuberans and dermatofibroma: Lack of correlation with proliferation rate. J Cutan Pathol 1995;22:304-9. [DOI: 10.1111/j.1600-0560.1995.tb01412.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
143 Hara A, Saegusa M, Mitomi H, Kurihara M, Ishihara K, Hotta K, Okayasu I. Colonic Mucin-Carbohydrate Components in Colorectal Tumors and Their Possible Relationship to MUC2, p53 and DCC Immunoreactivities. Pathology - Research and Practice 2000;196:159-66. [DOI: 10.1016/s0344-0338(00)80096-5] [Cited by in Crossref: 7] [Article Influence: 0.3] [Reference Citation Analysis]
144 Kinsella AR, Smith D, Pickard M. Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. Br J Cancer. 1997;75:935-945. [PMID: 9083327 DOI: 10.1038/bjc.1997.164] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 2.7] [Reference Citation Analysis]
145 van Rensburg EJ, Ponder BA. Molecular genetics of familial breast-ovarian cancer. J Clin Pathol 1995;48:789-95. [PMID: 7490308 DOI: 10.1136/jcp.48.9.789] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
146 Tullo A, D'Erchia AM, Honda K, Kelly MD, Habib NA, Saccone C, Sbisà E. New p53 mutations in hilar cholangiocarcinoma. Eur J Clin Invest 2000;30:798-803. [PMID: 10998080 DOI: 10.1046/j.1365-2362.2000.00717.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
147 Papanastassiou I, Ioannou M, Papagelopoulos PJ, Arealis G, Mihas C, Iakovidou I, Demertzis N. P53 expression as a prognostic marker in giant cell tumor of bone: a pilot study. Orthopedics 2010;33. [PMID: 20506947 DOI: 10.3928/01477447-20100329-15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
148 Bocchetta M, Carbone M. Epidemiology and molecular pathology at crossroads to establish causation: molecular mechanisms of malignant transformation. Oncogene. 2004;23:6484-6491. [PMID: 15322519 DOI: 10.1038/sj.onc.1207855] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
149 Pollina L, Pacini F, Fontanini G, Vignati S, Bevilacqua G, Basolo F. bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. Br J Cancer 1996;73:139-43. [PMID: 8546897 DOI: 10.1038/bjc.1996.26] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 2.2] [Reference Citation Analysis]
150 Nielsen HJ. Detrimental effects of perioperative blood transfusion. Br J Surg. 1995;82:582-587. [PMID: 7613921 DOI: 10.1002/bjs.1800820505] [Cited by in Crossref: 156] [Cited by in F6Publishing: 133] [Article Influence: 6.0] [Reference Citation Analysis]
151 Von Gruenigen VE, O'Boyle JD, Coleman RL, Wilson D, Miller DS, Mathis JM. Efficacy of intraperitoneal adenovirus-mediated p53 gene therapy in ovarian cancer. Int J Gynecol Cancer 1999;9:365-72. [PMID: 11240795 DOI: 10.1046/j.1525-1438.1999.99040.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
152 Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, Buffa R, Ferrero S, Piazza M, Blandamura S, Segalin A, Bonavina L, Peracchia A. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer 1997;79:425-32. [PMID: 9028350 DOI: 10.1002/(sici)1097-0142(19970201)79:3<425::aid-cncr1>3.0.co;2-h] [Cited by in Crossref: 114] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
153 Maehara Y, Kakeji Y, Watanabe A, Baba H, Kusumoto H, Kohnoe S, Sugimachi K. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer 1999;85:302-8. [DOI: 10.1002/(sici)1097-0142(19990115)85:2<302::aid-cncr6>3.0.co;2-6] [Cited by in Crossref: 29] [Article Influence: 1.3] [Reference Citation Analysis]
154 Juang JL, Hoffmann FM. Drosophila abelson interacting protein (dAbi) is a positive regulator of abelson tyrosine kinase activity. Oncogene 1999;18:5138-47. [PMID: 10498863 DOI: 10.1038/sj.onc.1202911] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 2.2] [Reference Citation Analysis]
155 Qin Q, Baudry M, Liao G, Noniyev A, Galeano J, Bi X. A novel function for p53: regulation of growth cone motility through interaction with Rho kinase. J Neurosci 2009;29:5183-92. [PMID: 19386914 DOI: 10.1523/JNEUROSCI.0420-09.2009] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
156 Jones L, Hoban P, Metcalfe P. The use of the linear quadratic model in radiotherapy: a review. Australas Phys Eng Sci Med 2001;24:132-46. [PMID: 11764395 DOI: 10.1007/BF03178355] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
157 López M, Anzola M, Cuevas-salazar N, Aguirre J, Martinez de Pancorbo M. p53, un gen supresor tumoral. Gaceta Médica de Bilbao 2001;98:21-7. [DOI: 10.1016/s0304-4858(01)74350-8] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
158 Kraegel SA, Pazzi KA, Madewell BR. Sequence analysis of canine p53 in the region of exons 3–8. Cancer Letters 1995;92:181-6. [DOI: 10.1016/0304-3835(95)03779-v] [Cited by in Crossref: 15] [Article Influence: 0.6] [Reference Citation Analysis]
159 Kuhlmann T, Glas M, zum Bruch C, Mueller W, Weber A, Zipp F, Brück W. Investigation of bax, bcl-2, bcl-x and p53 gene polymorphisms in multiple sclerosis. J Neuroimmunol 2002;129:154-60. [PMID: 12161031 DOI: 10.1016/s0165-5728(02)00167-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
160 Bae SK, Gwak J, Song IS, Park HS, Oh S. Induction of apoptosis in colon cancer cells by a novel topoisomerase I inhibitor TopIn. Biochem Biophys Res Commun 2011;409:75-81. [PMID: 21549095 DOI: 10.1016/j.bbrc.2011.04.108] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
161 Kimmelman A, Liang BC. FAMILIAL NEUROGENIC TUMOR SYNDROMES. Hematology/Oncology Clinics of North America 2001;15:1073-84. [DOI: 10.1016/s0889-8588(05)70268-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
162 Singer MJ, Mesner LD, Friedman CL, Trask BJ, Hamlin JL. Amplification of the human dihydrofolate reductase gene via double minutes is initiated by chromosome breaks. Proc Natl Acad Sci U S A 2000;97:7921-6. [PMID: 10859355 DOI: 10.1073/pnas.130194897] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 3.6] [Reference Citation Analysis]
163 Noguchi K, Nakajima M, Naito M, Tsuruo T. Inhibition by differentiation-inducing agents of wild-type p53-dependent apoptosis in HL-60 cells. Jpn J Cancer Res 1995;86:217-23. [PMID: 7730147 DOI: 10.1111/j.1349-7006.1995.tb03042.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
164 Vora H, Trivedi T, Shukla S, Shah N, Goswami J, Shah P. p53 Expression in Leukoplakia and Carcinoma of the Tongue. Int J Biol Markers 2006;21:74-80. [DOI: 10.1177/172460080602100202] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
165 van Haaften-day C, Russell P, Boyer CM, Kerns BM, Wiener JR, Jensen DN, Bast RC, Hacker NF. Expression of cell regulatory proteins in ovarian borderline tumors. Cancer 1996;77:2092-8. [DOI: 10.1002/(sici)1097-0142(19960515)77:10<2092::aid-cncr19>3.0.co;2-q] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
166 Kropveld A, Slootweg PJ, van Mansfeld ADM, Blankenstein MA, Hordijk GJ. Radioresistance and p53 status of T2 laryngeal carcinoma: Analysis by immunohistochemistry and denaturing gradient gel electrophoresis. Cancer 1996;78:991-7. [DOI: 10.1002/(sici)1097-0142(19960901)78:5<991::aid-cncr8>3.0.co;2-f] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
167 Smith PD, Crossland S, Parker G, Osin P, Brooks L, Waller J, Philp E, Crompton MR, Gusterson BA, Allday MJ, Crook T. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions. Oncogene 1999;18:2451-9. [PMID: 10229196 DOI: 10.1038/sj.onc.1202565] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 3.1] [Reference Citation Analysis]
168 Shimada S, Shiomori K, Tashima S, Tsuruta J, Ogawa M. Frequent p53 mutation in brain (fetal)-type glycogen phosphorylase positive foci adjacent to human 'de novo' colorectal carcinomas. Br J Cancer 2001;84:1497-504. [PMID: 11384100 DOI: 10.1054/bjoc.2001.1824] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
169 Bayly AC, Roberts RA, Dive C. Mechanisms of Apoptosis. Mechanisms of Cell Toxicity. Elsevier; 1997. pp. 183-229. [DOI: 10.1016/s1569-2558(08)60275-1] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
170 Min KW, Park MH, Hong SR, Lee H, Kwon SY, Hong SH, Joo HJ, Park IA, An HJ, Suh KS, Oh HK, Yoo CW, Kim MJ, Chang HK, Jun SY, Yoon HK, Chang ED, Kim DW, Kim I; Gynecologic Pathology Study Group of the Korean Society of Pathologists. Clear cell carcinomas of the ovary: a multi-institutional study of 129 cases in Korea with prognostic significance of Emi1 and Galectin-3. Int J Gynecol Pathol 2013;32:3-14. [PMID: 23202783 DOI: 10.1097/PGP.0b013e31825554e9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
171 Prieto Prieto I, Prieto Fenech A, Bascones Martínez A. Cáncer oral. Medicina Clínica 2006;127:258-64. [DOI: 10.1157/13091267] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
172 Mayr B, Blauensteiner J, Edlinger A, Reifinger M, Alton K, Schaffner G, Brem G. Presence of p53 mutations in feline neoplasms. Research in Veterinary Science 2000;68:63-9. [DOI: 10.1053/rvsc.1999.0339] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
173 Marxsen J, Schmiegel W, Röder C, Harder R, Juhl H, Henne-Bruns D, Kremer B, Kalthoff H. Detection of the anti-p53 antibody response in malignant and benign pancreatic disease. Br J Cancer 1994;70:1031-4. [PMID: 7947080 DOI: 10.1038/bjc.1994.443] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
174 Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Matsuoka Y, Yamashita H, Fukuda M, Higuchi A. Apoptosis in breast cancer and its relationship to clinicopathological characteristics and prognosis. J Surg Oncol 1999;71:226-34. [DOI: 10.1002/(sici)1096-9098(199908)71:4<226::aid-jso4>3.0.co;2-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
175 Hu T, Miller CM, Ridder GM, Aardema MJ. Characterization of p53 in Chinese hamster cell lines CHO-K1, CHO-WBL, and CHL: implications for genotoxicity testing. Mutat Res 1999;426:51-62. [PMID: 10320750 DOI: 10.1016/s0027-5107(99)00077-9] [Cited by in Crossref: 68] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
176 Lee H, Sun D, Larner JM, Wu F. The tumor suppressor p53 can reduce stable transfection in the presence of irradiation. J Biomed Sci 1999;6:285-92. [DOI: 10.1007/bf02253570] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
177 Yamashita T, Tonoki H, Nakata D, Yamano S, Segawa K, Moriuchi T. Adenovirus Type 5 E1A Immortalizes Primary Rat Cells Expressing Wild-Type p53. Microbiology and Immunology 1999;43:1037-44. [DOI: 10.1111/j.1348-0421.1999.tb01233.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
178 De Vries J, Ten Kate J, Bosman F. p21ras in Carcinogenesis. Pathology - Research and Practice 1996;192:658-68. [DOI: 10.1016/s0344-0338(96)80087-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
179 Blom R, Guerrieri C, Stål O, Malmström H, Simonsen E. Leiomyosarcoma of the Uterus: A Clinicopathologic, DNA Flow Cytometric, p53, and mdm-2 Analysis of 49 Cases. Gynecologic Oncology 1998;68:54-61. [DOI: 10.1006/gyno.1997.4889] [Cited by in Crossref: 75] [Cited by in F6Publishing: 60] [Article Influence: 3.3] [Reference Citation Analysis]
180 Venitt S. Mechanisms of spontaneous human cancers. Environ Health Perspect 1996;104 Suppl 3:633-7. [PMID: 8781396 DOI: 10.1289/ehp.96104s3633] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
181 Neumann HP, Zbar B. Renal cysts, renal cancer and von Hippel-Lindau disease. Kidney International 1997;51:16-26. [DOI: 10.1038/ki.1997.3] [Cited by in Crossref: 68] [Cited by in F6Publishing: 51] [Article Influence: 2.8] [Reference Citation Analysis]
182 Seo YH, Joo YE, Choi SK, Rew JS, Park CS, Kim SJ. Prognostic significance of p21 and p53 expression in gastric cancer. Korean J Intern Med. 2003;18:98-103. [PMID: 12872447 DOI: 10.3904/kjim.2003.18.2.98] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
183 Puglisi F, Di Loreto C, Panizzo R, Avellini C, Fongione S, Cacitti V, Beltrami CA. Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the oesophagus. J Clin Pathol 1996;49:456-9. [PMID: 8763257 DOI: 10.1136/jcp.49.6.456] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
184 Madhukar BV, Trosko JE. The causes of cancer: Implications for prevention and treatment. Indian J Pediatr 1997;64:131-41. [DOI: 10.1007/bf02752430] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]
185 Konstantinidou AE, Pavlopoulos PM, Patsouris E, Kaklamanis L, Davaris P. Expression of apoptotic and proliferation markers in meningiomas. J Pathol 1998;186:325-30. [DOI: 10.1002/(sici)1096-9896(1998110)186:3<325::aid-path168>3.0.co;2-u] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
186 Hunt CR, Hale RJ, Buckley CH, Hunt J. p53 expression in carcinoma of the cervix. J Clin Pathol 1996;49:971-4. [PMID: 9038732 DOI: 10.1136/jcp.49.12.971] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
187 Farrell WE, Clayton RN. Molecular Pathogenesis of Pituitary Tumors. Frontiers in Neuroendocrinology 2000;21:174-98. [DOI: 10.1006/frne.1999.0195] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 2.3] [Reference Citation Analysis]
188 Seregni E, Ferrari L, Martinetti A, Bombardieri E. Diagnostic and prognostic tumor markers in the gastrointestinal tract. Semin Surg Oncol 2001;20:147-66. [PMID: 11398208 DOI: 10.1002/ssu.1028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
189 López-guerrero J, Bolufer-gilabert P, Marugán de la Concha I, Barragán-gonzález E, Vera-sempere F. Relationship of p53 molecular abnormalities with flow cytometry and growth factor receptor content in lung cancer. Clinica Chimica Acta 1998;269:63-76. [DOI: 10.1016/s0009-8981(97)00186-1] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
190 Jansson A, Gentile M, Sun X. p53 Mutations are present in colorectal cancer with cytoplasmic p53 accumulation. Int J Cancer 2001;92:338-41. [DOI: 10.1002/ijc.1189] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
191 Siufi Neto J, Kho RM, Siufi DF, Baracat EC, Anderson KS, Abrão MS. Cellular, histologic, and molecular changes associated with endometriosis and ovarian cancer. J Minim Invasive Gynecol 2014;21:55-63. [PMID: 23962574 DOI: 10.1016/j.jmig.2013.07.021] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
192 Huang X, Tajima K, Hamajima N, Xiang J, Inoue M, Hirose K, Tominaga S, Takezaki T, Kuroishi T, Tokudome S. Comparison of lifestyle and risk factors among Japanese with and without gastric cancer family history. Int J Cancer 2000;86:421-4. [DOI: 10.1002/(sici)1097-0215(20000501)86:3<421::aid-ijc18>3.0.co;2-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
193 Blom, Guerrieri. Adenosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53 and mdm-2 analysis of 11 cases. Int J Gynecol Cancer 1999;9:37-43. [DOI: 10.1046/j.1525-1438.1999.09885.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
194 Lee M, Yu S, Lee YS, Park JS. Characterization of nuclear factors binding to AT-rich element in the rat p53 promoter. J Cell Biochem 2001;80:580-8. [PMID: 11169742 DOI: 10.1002/1097-4644(20010315)80:4<580::aid-jcb1012>3.0.co;2-c] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
195 Williams AC, Miller JC, Collard T, Browne SJ, Newbold RF, Paraskeva C. The effect of differentTP53 mutations on the chromosomal stability of a human colonic adenoma derived cell line with endogenous wild type TP53 activity, before and after DNA damage. Genes Chromosom Cancer 1997;20:44-52. [DOI: 10.1002/(sici)1098-2264(199709)20:1<44::aid-gcc7>3.0.co;2-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
196 Wang L, Jiang H, Li W, Jia C, Zhang H, Sun Y, Chen X, Song X. Overexpression of TP53 mutation-associated microRNA-182 promotes tumor cell proliferation and migration in head and neck squamous cell carcinoma. Archives of Oral Biology 2017;73:105-12. [DOI: 10.1016/j.archoralbio.2016.09.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
197 Ellison DW, Lunec J, Gallagher PJ, Steart PV, Jaros E, Gatter KC. Accumulation of wild-type p53 in meningiomas. Neuropathol Appl Neurobiol 1995;21:136-42. [PMID: 7609844 DOI: 10.1111/j.1365-2990.1995.tb01040.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 1.0] [Reference Citation Analysis]
198 Zhuang XQ, Yuan SZ, Wang XH, Lai RQ, Luo ZQ. Oncoprotein expression and inhibition of apoptosis during colorectal tumorigenesis. World J Gastroenterol 1996; 2(1): 3-5 [DOI: 10.3748/wjg.v2.i1.3] [Reference Citation Analysis]
199 Shima K, Kobayashi I, Saito I, Kiyoshima T, Matsuo K, Ozeki S, Ohishi M, Sakai H. Incidence of human papillomavirus 16 and 18 infection and p53 mutation in patients with oral squamous cell carcinoma in Japan. British Journal of Oral and Maxillofacial Surgery 2000;38:445-50. [DOI: 10.1054/bjom.2000.0162] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
200 Riou G, Barrois M, Prost S, Terrier MJ, Theodore C, Levine AJ. Thep53 andmdm-2 genes in human testicular germ-cell tumors. Mol Carcinog 1995;12:124-31. [DOI: 10.1002/mc.2940120303] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 2.5] [Reference Citation Analysis]
201 González IA, Mallinger P, Watson D, Harris AK, Messinger YH, Schultz KAP, Field A, Hill DA, Dehner LP. Expression of p53 is significantly associated with recurrence-free survival and overall survival in pleuropulmonary blastoma (PPB): a report from the International Pleuropulmonary Blastoma/DICER1 Registry. Mod Pathol 2021;34:1104-15. [PMID: 33637876 DOI: 10.1038/s41379-021-00735-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
202 Honma M. Generation of loss of heterozygosity and its dependency on p53 status in human lymphoblastoid cells. Environ Mol Mutagen 2005;45:162-76. [DOI: 10.1002/em.20113] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
203 Rudolph P, Alm P, Olsson H, Heidebrecht HJ, Fernö M, Baldetorp B, Parwaresch R. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer. Hum Pathol 2001;32:311-9. [PMID: 11274641 DOI: 10.1053/hupa.2001.22748] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
204 Barton CM, Lemoine NR. Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. Br J Cancer 1995;71:429-37. [PMID: 7880719 DOI: 10.1038/bjc.1995.88] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 1.4] [Reference Citation Analysis]
205 Geisler JP, Geisler HE, Wiemann MC, Zhou Z, Miller GA, Crabtree W. p53 Expression as a Prognostic Indicator of 5-Year Survival in Endometrial Cancer. Gynecologic Oncology 1999;74:468-71. [DOI: 10.1006/gyno.1999.5482] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 2.0] [Reference Citation Analysis]
206 Buttgereit P, Schmidt-wolf IG. Gene Therapy of Lymphoma. Journal of Hematotherapy & Stem Cell Research 2002;11:457-67. [DOI: 10.1089/15258160260090924] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
207 Ofner D, Maier H, Riedmann B, Holzberger P, Nogler M, Tötsch M, Bankfalvi A, Winde G, Böcker W, Schmid KW. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in colorectal carcinoma: prognostic significance. Clin Mol Pathol 1995;48:M12-6. [PMID: 16695968 DOI: 10.1136/mp.48.1.m12] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
208 Im HJ, Pittelkow MR, Kumar R. Divergent regulation of the growth-promoting gene IEX-1 by the p53 tumor suppressor and Sp1. J Biol Chem 2002;277:14612-21. [PMID: 11844788 DOI: 10.1074/jbc.M109414200] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
209 Kochetkov DV, Ilyinskaya GV, Komarov PG, Strom E, Agapova LS, Ivanov AV, Budanov AV, Frolova EI, Chumakov PM. Transcriptional inhibition of the human papilloma virus reactivates tumor suppressor p53 in cervical carcinoma cells. Mol Biol 2007;41:459-66. [DOI: 10.1134/s0026893307030120] [Cited by in Crossref: 16] [Article Influence: 1.1] [Reference Citation Analysis]
210 Pocard M, Debruyne P, Bras-gonçalves R, Mareel M, Dutrillaux B, Poupon M. Single alteration of p53 or E-cadherin genes can alter the surgical resection benefit in an experimental model of colon cancer. Diseases of the Colon & Rectum 2001;44:1106-12. [DOI: 10.1007/bf02234630] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
211 Smit EF, Groen HJ, Splinter TA, Ebels T, Postmus PE. New prognostic factors in resectable non-small cell lung cancer. Thorax 1996;51:638-46. [PMID: 8693450 DOI: 10.1136/thx.51.6.638] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
212 Schmid KW, Bankfalvi A, Mücke S, Öfner D, Riehemann K, Schröder S, Stücker A, Tötsch M, Dockhorn-dworniczak B. Possible relation of p53 and mdm-2 oncoprotein expression in thyroid carcinoma: A molecular-pathological and immunohistochemical study on paraffin-embedded tissue. Endocr Pathol 1996;7:121-30. [DOI: 10.1007/bf02739971] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
213 Mirzayans R, Aubin RA, Bosnich W, Blattner WA, Paterson MC. Abnormal pattern of post-gamma-ray DNA replication in radioresistant fibroblast strains from affected members of a cancer-prone family with Li-Fraumeni syndrome. Br J Cancer 1995;71:1221-30. [PMID: 7779715 DOI: 10.1038/bjc.1995.237] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.6] [Reference Citation Analysis]
214 Lee H, Park G, Jung J, Ahn W, Lee J, Kim B, Kang C. Diagnostic approach using the expression profiling of the P53 tumor suppressor gene and its related proteins in ovarian epithelial tumors. Int J Gynecol Cancer 2005;15:453-61. [DOI: 10.1111/j.1525-1438.2005.15308.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
215 Brett MC, Pickard M, Green B, Howel-Evans A, Smith D, Kinsella A, Poston G. p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur J Surg Oncol 1996;22:182-5. [PMID: 8608838 DOI: 10.1016/s0748-7983(96)90827-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
216 Farid NR, Zou M, Shi Y. Genetics of Follicular Thyroid Cancer. Endocrinology and Metabolism Clinics of North America 1995;24:865-83. [DOI: 10.1016/s0889-8529(18)30024-0] [Cited by in Crossref: 27] [Article Influence: 1.0] [Reference Citation Analysis]
217 Tashima S, Shimada S, Yamaguchi K, Tsuruta J, Ogawa M. Expression of brain-type glycogen phosphorylase is a potentially novel early biomarker in the carcinogenesis of human colorectal carcinomas. Am J Gastroenterol. 2000;95:255-263. [PMID: 10638593 DOI: 10.1111/j.1572-0241.2000.01692.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
218 Uberti D, Lanni C, Carsana T, Francisconi S, Missale C, Racchi M, Govoni S, Memo M. Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients. Neurobiol Aging 2006;27:1193-201. [PMID: 16165254 DOI: 10.1016/j.neurobiolaging.2005.06.013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
219 El-habashil A, Freeman S, El-morsi B, Morris GF, Marroqi A. p53 and PCNA Coexpression of 81 Pleural and Peritoneal Effusion Specimens: An Immunohistochemical Study. Pathology - Research and Practice 1996;192:834-9. [DOI: 10.1016/s0344-0338(96)80057-4] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
220 Skuse GR. The search for prognostic genetic indicators of cancer recurrence. International Journal of Radiation Oncology*Biology*Physics 1996;34:509-10. [DOI: 10.1016/0360-3016(95)02194-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
221 Tsang W, Chau SPY, Fung K, Kong S, Kwok T. Modulation of multidrug resistance-associated protein 1 (MRP1) by p53 mutant in Saos-2 cells. Cancer Chemother Pharmacol 2003;51:161-6. [DOI: 10.1007/s00280-002-0551-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
222 Chakravarty G, Redkar A, Mittra I. A comparative study of detection of p53 mutations in human breast cancer by flow cytometry, single-strand conformation polymorphism and genomic sequencing. Br J Cancer 1996;74:1181-7. [PMID: 8883402 DOI: 10.1038/bjc.1996.514] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
223 Wu F, Cao W, Xu H, Zhu M, Wang J, Ke X. Treatment with a selenium-platinum compound induced T-cell acute lymphoblastic leukemia/lymphoma cells apoptosis through the mitochondrial signaling pathway. Oncol Lett 2017;13:1702-10. [PMID: 28454312 DOI: 10.3892/ol.2017.5666] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
224 Coggins LW, Scobie L, Jackson ME, Campo MS. Assignment of the bovine p53 gene (TP53) to Chromosome 19q15 by fluorescence in situ hybridization. Mammalian Genome 1995;6:687-8. [DOI: 10.1007/bf00352389] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
225 Bahethi RR, Stepan KO, Pinotti R, Li R, Agrawal N, Puram SV, Miles BA, Barber B. Genetic Mutations in Young Nonsmoking Patients With Oral Cavity Cancer: A Systematic Review. OTO Open 2020;4:2473974X20970181. [PMID: 33210069 DOI: 10.1177/2473974X20970181] [Reference Citation Analysis]
226 Høgdall EV, Høgdall CK, Blaakaer J, Christensen L, Bock JE, Vuust J, Glud E, Kjaer SK; Danish "Malova" Ovarian Cancer Study. K-ras alterations in Danish ovarian tumour patients. From the Danish "Malova" Ovarian Cancer study. Gynecol Oncol 2003;89:31-6. [PMID: 12694651 DOI: 10.1016/s0090-8258(03)00005-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
227 Rauth S, Green A, Kichina J, Shilkaitis A. Suppression of tumorigenic and metastatic potentials of human melanoma cell lines by mutated (143 Val-Ala) p53. Br J Cancer 1998;77:2215-22. [PMID: 9649136 DOI: 10.1038/bjc.1998.369] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
228 Tropé C. Prognostic factors in ovarian cancer. Cancer Treat Res 1998;95:287-352. [PMID: 9619290 DOI: 10.1007/978-1-4615-5447-9_11] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
229 Lutzker SG, Levine AJ. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat Med 1996;2:804-10. [PMID: 8673928 DOI: 10.1038/nm0796-804] [Cited by in Crossref: 125] [Cited by in F6Publishing: 122] [Article Influence: 5.0] [Reference Citation Analysis]
230 Klaunig JE, Kamendulis LM, Xu Y. Epigenetic mechanisms of chemical carcinogenesis. Hum Exp Toxicol 2000;19:543-55. [DOI: 10.1191/096032700701546442] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 12.6] [Reference Citation Analysis]
231 Thorlacius S, Thorgilsson B, Björnsson J, Tryggvadottir L, Börresen A, Ögmundsdottir H, Eyfjörd J. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. European Journal of Cancer 1995;31:1856-61. [DOI: 10.1016/0959-8049(95)00399-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 1.3] [Reference Citation Analysis]
232 Mester JL, Jackson SA, Postula K, Stettner A, Solomon S, Bissonnette J, Murphy PD, Klein RT, Hruska KS. Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel Testing. The Journal of Molecular Diagnostics 2020;22:396-404. [DOI: 10.1016/j.jmoldx.2019.12.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
233 Schneider-Stock R, Radig K, Oda Y, Mellin W, Rys J, Niezabitowski A, Roessner A. p53 gene mutations in soft-tissue sarcomas--correlations with p53 immunohistochemistry and DNA ploidy. J Cancer Res Clin Oncol 1997;123:211-8. [PMID: 9177493 DOI: 10.1007/BF01240317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.0] [Reference Citation Analysis]
234 Raybaud-Diogène H, Tétu B, Morency R, Fortin A, Monteil RA. p53 overexpression in head and neck squamous cell carcinoma: review of the literature. Eur J Cancer B Oral Oncol 1996;32B:143-9. [PMID: 8762869 DOI: 10.1016/0964-1955(95)00095-x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
235 Levine RA, Fleischli MA. Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines. Vet Pathol 2000;37:54-61. [PMID: 10643981 DOI: 10.1354/vp.37-1-54] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 2.2] [Reference Citation Analysis]
236 Faridoni-Laurens L, Bosq J, Janot F, Vayssade M, Le Bihan ML, Kaghad M, Caput D, Bénard J, Ahomadegbe JC. P73 expression in basal layers of head and neck squamous epithelium: a role in differentiation and carcinogenesis in concert with p53 and p63? Oncogene 2001;20:5302-12. [PMID: 11536043 DOI: 10.1038/sj.onc.1204687] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 1.7] [Reference Citation Analysis]
237 Chen Y, Lin-shiau S, Lin J. Involvement of Heat-Shock Protein 70 and P53 Proteins in Attenuation of UVC-lnduced Apoptosis by Thermal Stress in Hepatocellular Carcinoma Cells. Photochem Photobiol 1999;70:78-86. [DOI: 10.1111/j.1751-1097.1999.tb01952.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
238 Agapova LS, Ilyinskaya GV, Turovets NA, Ivanov AV, Chumakov PM, Kopnin BP. Chromosome changes caused by alterations of p53 expression. Mutat Res 1996;354:129-38. [PMID: 8692199 DOI: 10.1016/0027-5107(96)00062-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 1.5] [Reference Citation Analysis]
239 Carlson D, Williams J, Rollins-smith L, Christ C, John J, Williams C, Mckinnell R. Pronephric carcinoma: Chromosomes of cells rescued from apoptosis by an oncogenic herpesvirus detected with a polymerase chain reaction. Journal of Comparative Pathology 1995;113:277-86. [DOI: 10.1016/s0021-9975(05)80042-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
240 Pérez-Carro Ríos A, Lozano Ramírez A, García Caballero T, Labella Caballero T, Clemente García A. [An immunohistochemistry study of p53 protein in squamous cell carcinoma of the larynx]. Acta Otorrinolaringol Esp 2003;54:263-8. [PMID: 12825242 DOI: 10.1016/s0001-6519(03)78413-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
241 Mayr B, Schaffner W, Botto I, Reifinger M, Loupal G. Canine tumour suppressor gene p53--mutation in a case of adenoma of circumanal glands. Vet Res Commun 1997;21:369-73. [PMID: 9232781 DOI: 10.1023/a:1005820607258] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
242 Do TN, Rosal RV, Drew L, Raffo AJ, Michl J, Pincus MR, Friedman FK, Petrylak DP, Cassai N, Szmulewicz J, Sidhu G, Fine RL, Brandt-Rauf PW. Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. Oncogene 2003;22:1431-44. [PMID: 12629507 DOI: 10.1038/sj.onc.1206258] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 2.6] [Reference Citation Analysis]
243 Pangilinan F, Geiler K, Dolle J, Troendle J, Swanson DA, Molloy AM, Sutton M, Conley M, Kirke PN, Scott JM, Mills JL, Brody LC. Construction of a high resolution linkage disequilibrium map to evaluate common genetic variation in TP53 and neural tube defect risk in an Irish population. Am J Med Genet A 2008;146A:2617-25. [PMID: 18798306 DOI: 10.1002/ajmg.a.32504] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
244 Escuin D, Rosell R. The anti-apoptosis survivin gene and its role in human cancer: an overview. Clin Lung Cancer. 1999;1:138-143. [PMID: 14733665 DOI: 10.3816/CLC.1999.n.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
245 Tang S, Xu D, Zhou B. Analysis of P53 mutation and invasion front grading in oral squamous cell carcinomas. J Huazhong Univ Sci Technolog Med Sci 2010;30:525-9. [PMID: 20714883 DOI: 10.1007/s11596-010-0462-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
246 Kannan S, Chandran GJ, Pillai KR, Mathew B, Sujathan K, Nalinakumary KR, Nair MK. Expression of p53 in leukoplakia and squamous cell carcinoma of the oral mucosa: correlation with expression of Ki67. Clin Mol Pathol 1996;49:M170-5. [PMID: 16696067 DOI: 10.1136/mp.49.3.m170] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
247 Maehara Y, Tomoda M, Hasuda S, Kabashima A, Tokunaga E, Kakeji Y, Sugimachi K. Prognostic value of p53 protein expression for patients with gastric cancer--a multivariate analysis. Br J Cancer 1999;79:1255-61. [PMID: 10098768 DOI: 10.1038/sj.bjc.6690201] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.0] [Reference Citation Analysis]
248 Mayr B, Reifinger M, Loupal G. Polymorphisms in feline tumour suppressor gene p53.Mutations in an osteosarcoma and a mammary carcinoma. The Veterinary Journal 1998;155:103-6. [DOI: 10.1016/s1090-0233(98)80044-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
249 Kim SK, Wang KC, Cho BK, Jung HW, Lee YJ, Chung YS, Lee JY, Park SH, Kim YM, Choe G, Chi JG. Biological behavior and tumorigenesis of subependymal giant cell astrocytomas. J Neurooncol 2001;52:217-25. [PMID: 11519851 DOI: 10.1023/a:1010664311717] [Cited by in Crossref: 49] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
250 Doubrovin M, Ponomarev V, Beresten T, Balatoni J, Bornmann W, Finn R, Humm J, Larson S, Sadelain M, Blasberg R, Gelovani Tjuvajev J. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci U S A 2001;98:9300-5. [PMID: 11481488 DOI: 10.1073/pnas.161091198] [Cited by in Crossref: 156] [Cited by in F6Publishing: 112] [Article Influence: 7.8] [Reference Citation Analysis]
251 Popov Z, Hoznek A, Colombel M, Bastuji-garin S, Lefrere-belda M, Bellot J, Abbou CC, Mazerolles C, Chopin DK. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 1997;80:1472-81. [DOI: 10.1002/(sici)1097-0142(19971015)80:8<1472::aid-cncr15>3.0.co;2-2] [Cited by in Crossref: 66] [Article Influence: 2.8] [Reference Citation Analysis]
252 O'connor MM, Mayberg MR. Effects of Radiation on Cerebral Vasculature: A Review. Neurosurgery 2000;46:138-51. [DOI: 10.1093/neurosurgery/46.1.138] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 3.2] [Reference Citation Analysis]
253 Hagel C, Laking G, Laas R, Scheil S, Jung R, Milde-langosch K, Stavrou D. Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas. European Journal of Cancer 1996;32:2242-8. [DOI: 10.1016/s0959-8049(96)00259-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
254 Adnane J, Bizouarn FA, Qian Y, Hamilton AD, Sebti SM. p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: involvement of the small GTPase rhoA. Mol Cell Biol. 1998;18:6962-6970. [PMID: 9819384 DOI: 10.1128/mcb.18.12.6962] [Cited by in Crossref: 93] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
255 Sauter ER, Ridge JA, Klein-szanto A, Track B, Cleveland D, Whitley KV, Mohr RM. Overexpression of the p53 gene in primary and metastatic head and neck carcinomas. Laryngoscope 1995;105:653-6. [DOI: 10.1288/00005537-199506000-00018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
256 Lombardi T, Odell E, Morgan P. p53 Immunohistochemistry of odontogenic keratocysts in relation to recurrence, basal-cell budding and basal-cell naevus syndrome. Archives of Oral Biology 1995;40:1081-4. [DOI: 10.1016/0003-9969(95)00092-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.0] [Reference Citation Analysis]
257 Sironi G, Riccaboni P, Mertel L, Cammarata G, Brooks DE. p53 protein expression in conjunctival squamous cell carcinomas of domestic animals. Vet Ophthalmol 1999;2:227-31. [DOI: 10.1046/j.1463-5224.1999.00086.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
258 Zhang ZF, Zeng ZS, Sarkis AS, Klimstra DS, Charytonowicz E, Pollack D, Vena J, Guillem J, Marshall JR, Cordon-Cardo C. Family history of cancer, body weight, and p53 nuclear overexpression in Duke's C colorectal cancer. Br J Cancer. 1995;71:888-893. [PMID: 7710960 DOI: 10.1038/bjc.1995.171] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
259 Nabarra B, Pontoux C, Godard C, Osborne-Pellegrin M, Ezine S. Neoplastic transformation and angiogenesis in the thymus of transgenic mice expressing SV40 T and t antigen under an L-pyruvate kinase promoter (SV12 mice). Int J Exp Pathol 2005;86:397-413. [PMID: 16309545 DOI: 10.1111/j.0959-9673.2005.00451.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
260 Farrell WE, Clayton RN. Molecular Genetics of Pituitary Tumours. Trends in Endocrinology & Metabolism 1998;9:20-6. [DOI: 10.1016/s1043-2760(98)00006-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
261 Mineta H, Borg A, Dictor M, Wahlberg P, Akervall J, Wennerberg J. p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. Br J Cancer 1998;78:1084-90. [PMID: 9792155 DOI: 10.1038/bjc.1998.632] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 3.0] [Reference Citation Analysis]
262 Grebe SKG, Eberhardt NL, Jenkins RB. Cytogenetic Abnormalities Associated with Endocrine Neoplasia. In: Wolman SR, Sell S, editors. Human Cytogenetic Cancer Markers. Totowa: Humana Press; 1997. pp. 369-401. [DOI: 10.1007/978-1-4612-3952-9_14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
263 Blom R, Guerrieri C, Stål O, Malmström H, Sullivan S, Simonsen E. Malignant Mixed Müllerian Tumors of the Uterus: A Clinicopathologic, DNA Flow Cytometric, p53, and mdm-2 Analysis of 44 Cases. Gynecologic Oncology 1998;68:18-24. [DOI: 10.1006/gyno.1997.4892] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
264 Yamashita T, Tokino T, Tonoki H, Moriuchi T, Jin H, Omori F, Jimbow K. Induction of Apoptosis in Melanoma Cell Lines by p53 and its Related Proteins. Journal of Investigative Dermatology 2001;117:914-9. [DOI: 10.1046/j.0022-202x.2001.01464.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
265 Cantemir C, Cozmei C, Scutaru B, Nicoara S, Carasevici E. p53 protein expression in peripheral lymphocytes from atrazine chronically intoxicated rats. Toxicol Lett 1997;93:87-94. [PMID: 9486943 DOI: 10.1016/s0378-4274(97)00050-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
266 Sengupta P, Mcgown A, Bajaj V, Blackhall F, Swindell R, Bromley M, Shanks J, Ward T, Buckley C, Reynolds K, Slade R, Jayson G. p53 And related proteins in epithelial ovarian cancer. European Journal of Cancer 2000;36:2317-28. [DOI: 10.1016/s0959-8049(00)00301-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
267 Uittenbogaard MN, Giebler HA, Reisman D, Nyborg JK. Transcriptional Repression of p53 by Human T-cell Leukemia Virus Type I Tax Protein. Journal of Biological Chemistry 1995;270:28503-6. [DOI: 10.1074/jbc.270.48.28503] [Cited by in Crossref: 61] [Cited by in F6Publishing: 71] [Article Influence: 2.3] [Reference Citation Analysis]
268 Crea F, Nobili S, Paolicchi E, Perrone G, Napoli C, Landini I, Danesi R, Mini E. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist Updat. 2011;14:280-296. [PMID: 21955833 DOI: 10.1016/j.drup.2011.08.001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 74] [Article Influence: 7.4] [Reference Citation Analysis]
269 Tagawa M, Murata M, Kimura H. Prognostic value of mutations and a germ line polymorphism of the p53 gene in non-small cell lung carcinoma: association with clinicopathological features. Cancer Letters 1998;128:93-9. [DOI: 10.1016/s0304-3835(98)00056-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
270 Kinsella AR, Smith D. Tumor Resistance To Antimetabolites. General Pharmacology: The Vascular System 1998;30:623-6. [DOI: 10.1016/s0306-3623(97)00383-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
271 Waters MD, Stack H, Jackson MA. Genetic toxicology data in the evaluation of potential human environmental carcinogens. Mutation Research/Reviews in Mutation Research 1999;437:21-49. [DOI: 10.1016/s1383-5742(99)00037-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
272 Murray PV, Soussi T, O'Brien ME, Smith IE, Brossault S, Norton A, Ashley S, Tavassoli M. Serum p53 antibodies: predictors of survival in small-cell lung cancer? Br J Cancer 2000;83:1418-24. [PMID: 11076647 DOI: 10.1054/bjoc.2000.1475] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
273 Nobili S, Napoli C, Landini I, Morganti M, Cianchi F, Valanzano R, Tonelli F, Cortesini C, Mazzei T, Mini E. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer. Int J Cancer 2011;128:1935-45. [DOI: 10.1002/ijc.25514] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
274 Ball VA, Righi PD, Tejada E, Radpour S, Pavelic ZP, Gluckman JL. p53 Immunostaining of Surgical Margins as a Predictor of Local Recurrence in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx. Ear Nose Throat J 1997;76:818-23. [DOI: 10.1177/014556139707601109] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
275 Pauly M, Schmitz M, Kayser I, Lagoda P, Türeci Ö, Kerschen A, Weber J, Seitz G, Hentges F, Dicato M. Epidemiological study of p53 tumor suppressor gene mutations in patients from Luxembourg and the German Saar region with an advanced colorectal cancer using PCR-SSCP analysis. Biomedicine & Pharmacotherapy 1998;52:220-8. [DOI: 10.1016/s0753-3322(98)80020-6] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
276 Phillips H. The Role of the p53 Tumour Suppressor Gene in Human Breast Cancer. Clinical Oncology 1999;11:148-55. [DOI: 10.1053/clon.1999.9032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
277 Stål O, Askmalm MS, Wingren S, Rutqvist LE, Skoog L, Ferraud L, Sullivan S, Carstensen J, Nordenskjöld B. P53 Expression and the Result of Adjuvant Therapy of Breast Cancer. Acta Oncologica 2009;34:767-70. [DOI: 10.3109/02841869509127184] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
278 Van Orden K, Giebler HA, Lemasson I, Gonzales M, Nyborg JK. Binding of p53 to the KIX domain of CREB binding protein. A potential link to human T-cell leukemia virus, type I-associated leukemogenesis. J Biol Chem 1999;274:26321-8. [PMID: 10473588 DOI: 10.1074/jbc.274.37.26321] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 3.9] [Reference Citation Analysis]
279 Waters DJ. Tumor Metastasis: Current Biologic Concepts and Their Implications for Control of Residual Disease. Veterinary Clinics of North America: Small Animal Practice 1995;25:231-47. [DOI: 10.1016/s0195-5616(95)50015-4] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
280 Lin DL, Chang C. p53 is a mediator for radiation-repressed human TR2 orphan receptor expression in MCF-7 cells, a new pathway from tumor suppressor to member of the steroid receptor superfamily. J Biol Chem 1996;271:14649-52. [PMID: 8663350 DOI: 10.1074/jbc.271.25.14649] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 1.4] [Reference Citation Analysis]
281 Vieira FL, Vieira BJ, Guimaraes MA, Aarestrup FM. Cellular profile of the peritumoral inflammatory infiltrate in squamous cells carcinoma of oral mucosa: Correlation with the expression of Ki67 and histologic grading. BMC Oral Health 2008;8:25. [PMID: 18764952 DOI: 10.1186/1472-6831-8-25] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
282 Huang YD, Li P, Tong X, He Y, Zhuo Y, Xia SW, Luo XH. Effects of bleomycin A5 on caspase-3, P53, bcl-2 expression and telomerase activity in vascular endothelial cells. Indian J Pharmacol 2015;47:55-8. [PMID: 25821312 DOI: 10.4103/0253-7613.150337] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
283 Garcia CA, Ahmadian A, Gharizadeh B, Lundeberg J, Ronaghi M, Nyrén P. Mutation detection by pyrosequencing: sequencing of exons 5-8 of the p53 tumor suppressor gene. Gene. 2000;253:249-257. [PMID: 10940563 DOI: 10.1016/S0378-1119(00)00257-2] [Cited by in Crossref: 54] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
284 Nylander K, Schildt EB, Eriksson M, Magnusson A, Mehle C, Roos G. A non-random deletion in the p53 gene in oral squamous cell carcinoma. Br J Cancer 1996;73:1381-6. [PMID: 8645583 DOI: 10.1038/bjc.1996.262] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
285 Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E, Klompmaker R, Peterse J. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 1996;73:728-34. [PMID: 8611372 DOI: 10.1038/bjc.1996.128] [Cited by in Crossref: 114] [Cited by in F6Publishing: 111] [Article Influence: 4.6] [Reference Citation Analysis]